Clinical Trial Update: Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care

View source ↗

Summary

A completed clinical trial from Wyeth/Pfizer investigates whether targeted antibiotic use can reduce infections with vancomycin-resistant Enterococcus and ESBL-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Escherichia Coli Infection
• Klebsiella Pneumoniae Infection
• Vancomycin-resistant Enterococcal Infection

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Escherichia Coli Infections, Klebsiella Infections | Status: COMPLETED